Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Agilysys Inc (AGYS) Price & Performance

AbbVie IncTrade
Agilysys IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Agilysys Inc — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Agilysys Inc trades at $106.06 (market cap $3.02B). The key difference: AbbVie Inc is far larger — about 145.1× Agilysys Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.

ABBVAGYS
Market Cap
$438.19B$3.02B
Sector
HealthTechnology
52-Week High
$263.58$141.12
52-Week Low
$197.38$62.19
Enterprise Value
$502.45B$2.92B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Agilysys Inc

Agilysys (AGYS) trades at $108.58, up 0.93% with strong bullish momentum supported by recent earnings beats and positive analyst sentiment. The stock shows robust fundamental performance with Q1 2026 EPS of $0.63 beating expectations and record subscription revenue growth. Technical indicators suggest bullish momentum with the current price near pivot point resistance at $108, while moving averages signal continued upward trend potential.

The outlook remains positive with 100% analyst buy ratings and a $118.33 consensus price target representing 9% upside. Key catalysts include continued subscription growth and Marriott deployment progress, though elevated valuation multiples (P/E 70.45) and competitive pressures in hospitality software present risks requiring monitoring of execution consistency.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Agilysys Inc

Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.

Read more on AGYS